Stay updated with breaking news from Manageable Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all
Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination...
24.05.2022 - - Results Showed Statistically Significant Improvement in Progression-Free Survival (PFS) Compared to Placebo (Hazard Ratio (HR) = 0.29; P
Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of